No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Zhejiang CONBA Pharmaceutical Co., Ltd., a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd., is headquartered in Hangzhou, China. Established in 1969, and formerly known as Lanxi Yunshan Pharmaceutical Factory until its name change in October 1999, the company specializes in the research, development, manufacturing, and distribution of traditional Chinese medicines and botanical products across China. Its broad portfolio extends to include chemical pharmaceuticals, proprietary Chinese medicines, vision care products, dietary supplements, general health supplies, everyday wellness goods, food items, and various personal care products.
www.conbapharm.comNo one on the platform currently holds 600572.SS.
No tracked institution reports a position in 600572.SS as of their last filing.
No one on the platform has traded 600572.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.6% | 15.1% | — | — | — | |
| Rev. Growth % | -0.6% | 1.8% | ||||
| Profit Margin % | 7.3% | 12.5% | 9.7% | |||
| Free Cash Flow Margin % | 12.3% | 10.6% | 9.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.2B | -10.4% | $0.23 | $0.23–$0.23 | — | 1 |
| 2027 | $8.0B | +10.4% | $0.28 | $0.28–$0.28 | — | 1 |
| 2028 | $8.7B | +9.8% | $0.33 | $0.33–$0.33 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600572.SSZhejiang CONBA Pharmaceutical Co.,Ltd. | $4.24 | +0.24% | $10.8B | — |
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.32 | +0.16% | $7.7B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.08 | -0.37% | $9.8B | — |
| 300181.SZZhejiang Jolly Pharmaceutical Co.,LTD | $13.18 | +0.15% | $9.1B | — |
| 600267.SSZhejiang Hisun Pharmaceutical Co., Ltd. |
| $11.36 |
| +0.53% |
| $13.4B |
| — |
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. | $19.16 | -0.57% | $10.9B | — |
| 600750.SSChina Resources Jiangzhong Pharmaceutical Co.,Ltd | $22.16 | +0.45% | $14.1B | — |
Source: Financial Modeling Prep · peers by sector/industry